151 related articles for article (PubMed ID: 14756005)
1. Therapy of chronic hepatitis B: today and tomorrow.
Trifan A; Stanciu C
Rev Med Chir Soc Med Nat Iasi; 2003; 107(4):689-98. PubMed ID: 14756005
[TBL] [Abstract][Full Text] [Related]
2. [Chronic hepatitis B virus infection].
Trifan A; Stanciu C
Rev Med Chir Soc Med Nat Iasi; 2003; 107(1):19-27. PubMed ID: 14755965
[TBL] [Abstract][Full Text] [Related]
3. Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy.
Suzuki F; Tsubota A; Akuta N; Someya T; Kobayashi M; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Miyakawa Y; Kumada H
J Gastroenterol; 2002; 37(11):922-7. PubMed ID: 12483247
[TBL] [Abstract][Full Text] [Related]
4. What is the optimal therapy for chronic hepatitis B?
Lyra AC; Di Bisceglie AM
Minerva Med; 2001 Dec; 92(6):431-4. PubMed ID: 11740431
[TBL] [Abstract][Full Text] [Related]
5. Interferon/long-term lamivudine combination therapy in anti-HBe positive chronic hepatitis B patients.
Nikolaidis NL; Giouleme OI; Tziomalos KA; Saveriadis AS; Grammatikos N; Doukelis P; Voutsas AD; Vassiliadis T; Patsiaoura K; Orfanou-Koumerkeridou E; Balaska A; Eugenidis NP
J Gastroenterol Hepatol; 2005 Nov; 20(11):1721-5. PubMed ID: 16246192
[TBL] [Abstract][Full Text] [Related]
6. [Future perspectives and strategies in managing resistance to analogue antiviral drugs in the treatment of chronic hepatitis B].
Bourlière M
Gastroenterol Clin Biol; 2006 Oct; 30(10 Pt 2):3S34-6. PubMed ID: 17075495
[No Abstract] [Full Text] [Related]
7. Estimating the future health burden of chronic hepatitis B and the impact of therapy in Spain.
Idris BI; Brosa M; Richardus JH; Esteban R; Schalm SW; Buti M
Eur J Gastroenterol Hepatol; 2008 Apr; 20(4):320-6. PubMed ID: 18334876
[TBL] [Abstract][Full Text] [Related]
8. In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B.
Horiike N; Fazle Akbar SM; Michitaka K; Joukou K; Yamamoto K; Kojima N; Hiasa Y; Abe M; Onji M
J Clin Virol; 2005 Feb; 32(2):156-61. PubMed ID: 15653419
[TBL] [Abstract][Full Text] [Related]
9. Remission of breakthrough hepatitis in chronic hepatitis B patients on lamivudine.
Koike K
J Gastroenterol; 2002; 37(11):988-90. PubMed ID: 12483259
[No Abstract] [Full Text] [Related]
10. One two tandem of lamivudine and inferferon might work for patients with chronic hepatitis B who failed inferferon monotherapy.
Kaplan DD; Reddy KR
Am J Gastroenterol; 2002 Sep; 97(9):2465-7. PubMed ID: 12358276
[No Abstract] [Full Text] [Related]
11. Combined interferon plus lamivudine treatment in young patients with dual HBV (HBeAg positive) and HCV chronic infection.
Marrone A; Zampino R; D'Onofrio M; Ricciotti R; Ruggiero G; Utili R
J Hepatol; 2004 Dec; 41(6):1064-5. PubMed ID: 15582146
[No Abstract] [Full Text] [Related]
12. Treatment of chronic hepatitis B: interferon alfa first.
Prescrire Int; 2001 Feb; 10(51):17-21. PubMed ID: 11503853
[TBL] [Abstract][Full Text] [Related]
13. Antiviral therapy for treatment-naïve hepatitis B virus patients.
Lau DT; Membreno FE
Gastroenterol Clin North Am; 2004 Sep; 33(3):581-99, ix-x. PubMed ID: 15324945
[TBL] [Abstract][Full Text] [Related]
14. Combined interferon and lamivudine therapy: is this the treatment of choice for patients with chronic hepatitis B virus infection?
Terrault NA
Hepatology; 2000 Sep; 32(3):675-7. PubMed ID: 10991635
[No Abstract] [Full Text] [Related]
15. Long-term lamivudine treatment is associated with a good maintained response in severe acute exacerbation of chronic HBeAg-negative hepatitis B.
Chan HL; Wong VW; Hui AY; Tsang SW; Chan JL; Chan HY; Wong GL; Sung JJ
Antivir Ther; 2006; 11(4):465-71. PubMed ID: 16856620
[TBL] [Abstract][Full Text] [Related]
16. Effect of long-term lamivudine in chronic hepatitis B virus-infected children.
Ozgenç F; Arikan C; Sertoz RY; Nart D; Aydogdu S; Yagci RV
Antivir Ther; 2004 Oct; 9(5):729-32. PubMed ID: 15535410
[TBL] [Abstract][Full Text] [Related]
17. Severe acute exacerbation of liver disease may reduce or delay emergence of YMDD motif mutants in long-term lamivudine therapy for hepatitis B e antigen-positive chronic hepatitis B.
Tsubota A; Arase Y; Suzuki F; Kobayashi M; Matsuda M; Sato J; Suzuki Y; Akuta N; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kumada H
J Med Virol; 2004 May; 73(1):7-12. PubMed ID: 15042641
[TBL] [Abstract][Full Text] [Related]
18. [Treatment strategies for viral hepatitis].
Matsushima T
Hokkaido Igaku Zasshi; 2002 Mar; 77(2):133-5. PubMed ID: 11968844
[No Abstract] [Full Text] [Related]
19. [Lamivudine treatment for hepatitis B].
Lamivudine Clincal Practice Group
Zhonghua Gan Zang Bing Za Zhi; 2004 Jul; 12(7):425-8. PubMed ID: 15487066
[No Abstract] [Full Text] [Related]
20. Therapy of chronic hepatitis B: new goals and new treatments.
Mauss S
Minerva Med; 2009 Dec; 100(6):447-58. PubMed ID: 20010480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
